GLP-1 Drugs Show Significant Health Benefits and Risks in Large-Scale Study
A study of over two million veterans found that GLP-1 drugs, such as Ozempic, significantly reduce risks of neurocognitive disorders, addiction, and self-harm, but also increase the risk of pancreatic and kidney problems.
GLP-1 Drugs Show Significant Health Benefits and Risks in Large-Scale Study
A study of over two million veterans found that GLP-1 drugs, such as Ozempic, significantly reduce risks of neurocognitive disorders, addiction, and self-harm, but also increase the risk of pancreatic and kidney problems.
Progress
52% Bias Score
GLP-1 Weight-Loss Drugs: Significant Health Benefits and Risks Revealed
A study of over 2.4 million people found that GLP-1 weight-loss medications reduced the risk of 42 health conditions, including cardiac arrest and Alzheimer's disease, by reducing inflammation and improving impulse control, but increased risks of gastrointestinal issues were also observed.
GLP-1 Weight-Loss Drugs: Significant Health Benefits and Risks Revealed
A study of over 2.4 million people found that GLP-1 weight-loss medications reduced the risk of 42 health conditions, including cardiac arrest and Alzheimer's disease, by reducing inflammation and improving impulse control, but increased risks of gastrointestinal issues were also observed.
Progress
36% Bias Score
Eli Lilly Stock Tumbles Despite Positive 2025 Outlook
Eli Lilly's stock fell over 7% on Tuesday after the company lowered its 2024 revenue outlook due to disappointing fourth-quarter sales of its GLP-1 weight-loss and diabetes drugs, Mounjaro and Zepbound, which missed estimates by a combined $500 million, despite resolving supply chain issues and main...
Eli Lilly Stock Tumbles Despite Positive 2025 Outlook
Eli Lilly's stock fell over 7% on Tuesday after the company lowered its 2024 revenue outlook due to disappointing fourth-quarter sales of its GLP-1 weight-loss and diabetes drugs, Mounjaro and Zepbound, which missed estimates by a combined $500 million, despite resolving supply chain issues and main...
Progress
40% Bias Score
Derby Football League Spurs Significant Weight Loss
A Derby, England, weight-loss football league, MAN v FAT, helped 47 players lose a combined 235kg (37 stone) in 2024, with some participants losing over a fifth of their body weight, improving their health and well-being.
Derby Football League Spurs Significant Weight Loss
A Derby, England, weight-loss football league, MAN v FAT, helped 47 players lose a combined 235kg (37 stone) in 2024, with some participants losing over a fifth of their body weight, improving their health and well-being.
Progress
32% Bias Score
NHS Wait Times Fuel Unsafe Online Weight-Loss Drug Purchases
Britain's top GP warns that long waits for NHS weight-loss services are driving people to buy potentially unsafe drugs online, as some patients face up to five-year waits for specialist support, while the NHS rollout of Mounjaro, a key weight-loss jab, is scheduled for 12 years, impacting an estimat...
NHS Wait Times Fuel Unsafe Online Weight-Loss Drug Purchases
Britain's top GP warns that long waits for NHS weight-loss services are driving people to buy potentially unsafe drugs online, as some patients face up to five-year waits for specialist support, while the NHS rollout of Mounjaro, a key weight-loss jab, is scheduled for 12 years, impacting an estimat...
Progress
48% Bias Score
FDA Approves Zepbound for Obstructive Sleep Apnea Treatment
The FDA approved Eli Lilly's Zepbound (tirzepatide) as the first medication to treat obstructive sleep apnea in obese adults, following two successful 52-week studies demonstrating significant symptom reduction.
FDA Approves Zepbound for Obstructive Sleep Apnea Treatment
The FDA approved Eli Lilly's Zepbound (tirzepatide) as the first medication to treat obstructive sleep apnea in obese adults, following two successful 52-week studies demonstrating significant symptom reduction.
Progress
32% Bias Score
GLP-1 Receptor Agonists: Significant Health Benefits and Risks Revealed in Large-Scale Study
A study of 1.4 million US veterans with type 2 diabetes showed that GLP-1 receptor agonists, weekly-injected drugs, reduced the risk of 42 health issues but increased the risk of 19 others, highlighting both benefits and risks of this increasingly popular medication.
GLP-1 Receptor Agonists: Significant Health Benefits and Risks Revealed in Large-Scale Study
A study of 1.4 million US veterans with type 2 diabetes showed that GLP-1 receptor agonists, weekly-injected drugs, reduced the risk of 42 health issues but increased the risk of 19 others, highlighting both benefits and risks of this increasingly popular medication.
Progress
36% Bias Score
GLP-1RA Medications: Reduced Risk of 42 Conditions, Increased Risk of 19 in Diabetic Patients
A study of 215,970 diabetic patients found GLP-1RA medications reduced the risk of 42 conditions (including psychotic disorders and dementia) by 13-19%, but increased the risk of 19 others (such as arthritis), based on a 3.5-year analysis of US Department of Veterans Affairs data.
GLP-1RA Medications: Reduced Risk of 42 Conditions, Increased Risk of 19 in Diabetic Patients
A study of 215,970 diabetic patients found GLP-1RA medications reduced the risk of 42 conditions (including psychotic disorders and dementia) by 13-19%, but increased the risk of 19 others (such as arthritis), based on a 3.5-year analysis of US Department of Veterans Affairs data.
Progress
40% Bias Score
Virta Health's 60% Revenue Surge Driven by Employer Demand for Cost-Effective Weight Loss Solutions
Virta Health, a digital diabetes and weight loss program, achieved 60% revenue growth in 2024, exceeding $100 million, due to increasing employer demand for cost-effective alternatives to expensive GLP-1 drugs; the company's nutrition-focused approach leads to an average 13% weight loss in a year, e...
Virta Health's 60% Revenue Surge Driven by Employer Demand for Cost-Effective Weight Loss Solutions
Virta Health, a digital diabetes and weight loss program, achieved 60% revenue growth in 2024, exceeding $100 million, due to increasing employer demand for cost-effective alternatives to expensive GLP-1 drugs; the company's nutrition-focused approach leads to an average 13% weight loss in a year, e...
Progress
40% Bias Score
Counterfeit Weight-Loss Injections Pose Serious Health Risks in the UK
UK health officials have seized over 600 fake weight-loss injection pens since 2023, causing serious health risks like seizures and comas due to the presence of insulin instead of the intended active ingredient. The illegal sale through online platforms and beauty salons is driven by high demand and...
Counterfeit Weight-Loss Injections Pose Serious Health Risks in the UK
UK health officials have seized over 600 fake weight-loss injection pens since 2023, causing serious health risks like seizures and comas due to the presence of insulin instead of the intended active ingredient. The illegal sale through online platforms and beauty salons is driven by high demand and...
Progress
52% Bias Score
Brain's Control of Intestinal Fat Absorption Suggests New Obesity Treatments
Researchers in Shanghai discovered that the brain regulates intestinal fat absorption in mice by controlling the length of microvilli in the jejunum via the vagus nerve; inactivating the nerve's dorsal motor nucleus reduces fat absorption and weight, while activation increases it, suggesting potenti...
Brain's Control of Intestinal Fat Absorption Suggests New Obesity Treatments
Researchers in Shanghai discovered that the brain regulates intestinal fat absorption in mice by controlling the length of microvilli in the jejunum via the vagus nerve; inactivating the nerve's dorsal motor nucleus reduces fat absorption and weight, while activation increases it, suggesting potenti...
Progress
36% Bias Score
Kathy Bates Showcases Dramatic Weight Loss at Hollywood Gala
Kathy Bates, 76, displayed her 100-pound weight loss at the Hollywood Reporter's Women in Entertainment Gala in Beverly Hills on Wednesday, openly discussing her health journey and use of Ozempic, while also reflecting on ageism in Hollywood.
Kathy Bates Showcases Dramatic Weight Loss at Hollywood Gala
Kathy Bates, 76, displayed her 100-pound weight loss at the Hollywood Reporter's Women in Entertainment Gala in Beverly Hills on Wednesday, openly discussing her health journey and use of Ozempic, while also reflecting on ageism in Hollywood.
Progress
56% Bias Score